Cargando…
Advancements in CRISPR screens for the development of cancer immunotherapy strategies
CRISPR screen technology enables systematic and scalable interrogation of gene function by using the CRISPR-Cas9 system to perturb gene expression. In the field of cancer immunotherapy, this technology has empowered the discovery of genes, biomarkers, and pathways that regulate tumor development and...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591018/ https://www.ncbi.nlm.nih.gov/pubmed/37876793 http://dx.doi.org/10.1016/j.omto.2023.100733 |
_version_ | 1785124130483339264 |
---|---|
author | Li, Yan-Ruide Lyu, Zibai Tian, Yanxin Fang, Ying Zhu, Yichen Chen, Yuning Yang, Lili |
author_facet | Li, Yan-Ruide Lyu, Zibai Tian, Yanxin Fang, Ying Zhu, Yichen Chen, Yuning Yang, Lili |
author_sort | Li, Yan-Ruide |
collection | PubMed |
description | CRISPR screen technology enables systematic and scalable interrogation of gene function by using the CRISPR-Cas9 system to perturb gene expression. In the field of cancer immunotherapy, this technology has empowered the discovery of genes, biomarkers, and pathways that regulate tumor development and progression, immune reactivity, and the effectiveness of immunotherapeutic interventions. By conducting large-scale genetic screens, researchers have successfully identified novel targets to impede tumor growth, enhance anti-tumor immune responses, and surmount immunosuppression within the tumor microenvironment (TME). Here, we present an overview of CRISPR screens conducted in tumor cells for the purpose of identifying novel therapeutic targets. We also explore the application of CRISPR screens in immune cells to propel the advancement of cell-based therapies, encompassing T cells, natural killer cells, dendritic cells, and macrophages. Furthermore, we outline the crucial components necessary for the successful implementation of immune-specific CRISPR screens and explore potential directions for future research. |
format | Online Article Text |
id | pubmed-10591018 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-105910182023-10-24 Advancements in CRISPR screens for the development of cancer immunotherapy strategies Li, Yan-Ruide Lyu, Zibai Tian, Yanxin Fang, Ying Zhu, Yichen Chen, Yuning Yang, Lili Mol Ther Oncolytics Review CRISPR screen technology enables systematic and scalable interrogation of gene function by using the CRISPR-Cas9 system to perturb gene expression. In the field of cancer immunotherapy, this technology has empowered the discovery of genes, biomarkers, and pathways that regulate tumor development and progression, immune reactivity, and the effectiveness of immunotherapeutic interventions. By conducting large-scale genetic screens, researchers have successfully identified novel targets to impede tumor growth, enhance anti-tumor immune responses, and surmount immunosuppression within the tumor microenvironment (TME). Here, we present an overview of CRISPR screens conducted in tumor cells for the purpose of identifying novel therapeutic targets. We also explore the application of CRISPR screens in immune cells to propel the advancement of cell-based therapies, encompassing T cells, natural killer cells, dendritic cells, and macrophages. Furthermore, we outline the crucial components necessary for the successful implementation of immune-specific CRISPR screens and explore potential directions for future research. American Society of Gene & Cell Therapy 2023-10-05 /pmc/articles/PMC10591018/ /pubmed/37876793 http://dx.doi.org/10.1016/j.omto.2023.100733 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Li, Yan-Ruide Lyu, Zibai Tian, Yanxin Fang, Ying Zhu, Yichen Chen, Yuning Yang, Lili Advancements in CRISPR screens for the development of cancer immunotherapy strategies |
title | Advancements in CRISPR screens for the development of cancer immunotherapy strategies |
title_full | Advancements in CRISPR screens for the development of cancer immunotherapy strategies |
title_fullStr | Advancements in CRISPR screens for the development of cancer immunotherapy strategies |
title_full_unstemmed | Advancements in CRISPR screens for the development of cancer immunotherapy strategies |
title_short | Advancements in CRISPR screens for the development of cancer immunotherapy strategies |
title_sort | advancements in crispr screens for the development of cancer immunotherapy strategies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591018/ https://www.ncbi.nlm.nih.gov/pubmed/37876793 http://dx.doi.org/10.1016/j.omto.2023.100733 |
work_keys_str_mv | AT liyanruide advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies AT lyuzibai advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies AT tianyanxin advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies AT fangying advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies AT zhuyichen advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies AT chenyuning advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies AT yanglili advancementsincrisprscreensforthedevelopmentofcancerimmunotherapystrategies |